Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Shares Issued (2016 - 2025)

Cytosorbents (CTSO) has disclosed Shares Issued for 13 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Shares Issued changed N/A year-over-year to $4.0 million, compared with a TTM value of $5.4 million through Sep 2025, up 9201.2%, and an annual FY2023 reading of $218278.0, changed N/A over the prior year.
  • Shares Issued was $4.0 million for Q3 2025 at Cytosorbents, up from -$828.0 in the prior quarter.
  • Across five years, Shares Issued topped out at $4.0 million in Q3 2025 and bottomed at -$828.0 in Q2 2025.
  • Average Shares Issued over 4 years is $497575.2, with a median of $53238.0 recorded in 2024.
  • Peak annual rise in Shares Issued hit 2604.51% in 2025, while the deepest fall reached 247.9% in 2025.
  • Year by year, Shares Issued stood at $9076.0 in 2021, then plummeted by 45.23% to $4971.0 in 2023, then plummeted by 104.79% to -$238.0 in 2024, then skyrocketed by 1661024.37% to $4.0 million in 2025.
  • Business Quant data shows Shares Issued for CTSO at $4.0 million in Q3 2025, -$828.0 in Q2 2025, and $1.4 million in Q1 2025.